GeoVax Labs Inc (GOVX) - Financial and Strategic SWOT Analysis Review

GeoVax Labs Inc (GOVX) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic, and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc Key Recent Developments

Aug 08,2024: GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Aug 06,2024: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 09,2024: GeoVax Provides First Half 2024 Business Update
May 29,2024: GeoVax to Present at BIO International Convention 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
GeoVax Labs Inc - Key Facts
GeoVax Labs Inc - Key Employees
GeoVax Labs Inc - Key Employee Biographies
GeoVax Labs Inc - Major Products and Services
GeoVax Labs Inc - History
GeoVax Labs Inc - Company Statement
GeoVax Labs Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
GeoVax Labs Inc - Business Description
R&D Overview
GeoVax Labs Inc - Corporate Strategy
GeoVax Labs Inc - SWOT Analysis
SWOT Analysis - Overview
GeoVax Labs Inc - Strengths
GeoVax Labs Inc - Weaknesses
GeoVax Labs Inc - Opportunities
GeoVax Labs Inc - Threats
GeoVax Labs Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
GeoVax Labs Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 08, 2024: GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Aug 06, 2024: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 09, 2024: GeoVax Provides First Half 2024 Business Update
May 29, 2024: GeoVax to Present at BIO International Convention 2024
May 14, 2024: Geovax Reports First Quarter 2024 Financial Results And Provides Business Update
May 07, 2024: GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
Mar 06, 2024: GeoVax Achieves Milestone In Transition To Commercially Validated Manufacturing System
Feb 29, 2024: GeoVax Reports 2023 Year-End Financial Results And Provides Business Update
Jan 08, 2024: GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Jan 03, 2024: GeoVax Announces Issuance of Malaria Vaccine Patent
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
GeoVax Labs Inc, Key Facts
GeoVax Labs Inc, Key Employees
GeoVax Labs Inc, Key Employee Biographies
GeoVax Labs Inc, Major Products and Services
GeoVax Labs Inc, History
GeoVax Labs Inc, Subsidiaries
GeoVax Labs Inc, Key Competitors
GeoVax Labs Inc, Ratios based on current share price
GeoVax Labs Inc, Annual Ratios
GeoVax Labs Inc, Annual Ratios (Cont...1)
GeoVax Labs Inc, Interim Ratios
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
GeoVax Labs Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
GeoVax Labs Inc, Performance Chart (2019 - 2023)
GeoVax Labs Inc, Ratio Charts
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings